Ovid Therapeutics
OVID
OVID
70 hedge funds and large institutions have $11.9M invested in Ovid Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
70
Holders Change
-12
Holders Change %
-14.63%
% of All Funds
0.94%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
17
Increased
16
Reduced
22
Closed
28
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
+$4K
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$353K |
| 2 |
Millennium Management
New York
|
+$347K |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$165K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$99.7K |
| 5 |
Goldman Sachs
New York
|
+$59.2K |
Top Sellers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.6M |
| 2 |
BlackRock
New York
|
-$822K |
| 3 |
JPMorgan Chase & Co
New York
|
-$397K |
| 4 |
MAP
Madison Avenue Partners
New York
|
-$381K |
| 5 |
State Street
Boston,
Massachusetts
|
-$378K |
